Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Toni Brand, PhD

    TitlePostdoctoral Scholar
    SchoolUCSF School of Medicine
    DepartmentOtolaryngology
    Address1450 Third St
    San Francisco CA 94158
    Phone415-502-3638
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 Sep; 15(9):2175-86. PMID: 27422810; PMCID: PMC5010956 [Available on 03/01/17].
      2. Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL. Adaptive responses to antibody based therapy. Semin Cell Dev Biol. 2016 Feb; 50:153-63. PMID: 26808665.
        View in: PubMed
      3. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 1; 21(11):2601-12. PMID: 25767293.
        View in: PubMed
      4. Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014; 13:242. PMID: 25344208; PMCID: PMC4283113.
      5. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64. PMID: 25136066; PMCID: PMC4167493.
      6. Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68. PMID: 24634415; PMCID: PMC4013210.
      7. Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84. PMID: 24327519; PMCID: PMC4286701.
      8. Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct; 15(10):1196-206. PMID: 24204198; PMCID: PMC3819635.
      9. Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med. 2013 Sep; 16(87):79-92. PMID: 23998444; PMCID: PMC3901945.
      10. Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. PLoS One. 2013; 8(8):e71518. PMID: 23951180; PMCID: PMC3738522.
      11. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013 Sep; 108(3):370-7. PMID: 23830194; PMCID: PMC3818450.
      12. Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther. 2013 Jun; 14(6):481-91. PMID: 23760490; PMCID: PMC3813564.
      13. Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91. PMID: 23792636; PMCID: PMC3742497.
      14. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41. PMID: 23628526; PMCID: PMC3679338.
      15. Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small GTPases. 2012 Jan-Mar; 3(1):34-9. PMID: 22714415; PMCID: PMC3398915.
      16. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med. 2011 Nov; 12(66):419-32. PMID: 22127113; PMCID: PMC3305885.
      17. Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther. 2011 Sep 1; 12(5):436-46. PMID: 21725209; PMCID: PMC3219082.
      18. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1; 11(9):777-92. PMID: 21293176; PMCID: PMC3100630.
      19. Brand TM, Wheeler DL. Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biol Ther. 2011 Feb 1; 11(3):368-70. PMID: 21228636.
        View in: PubMed
      Toni's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP